Associated Papers
Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK.
Tran KB et al.
Bmc Cancer, 2021
33549048 (PubMed )
Supplement: 12885_2021_7826_MOESM3_ESM.xlsx › Sheet1
Intratumoral KIT mutational heterogeneity and recurrent KIT/ PDGFRA mutations in KIT/PDGFRA wild-type gastrointestinal stromal tumors.
Gao J et al.
Oncotarget, 2016
26848617 (PubMed )
Supplement: oncotarget-07-30241-s002.xlsx › Sheet1
Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma.
Heidenreich B et al.
Nature Communications, 2014
Select a paper to view details